Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Danielle Sullivan

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
British Journal of Cancer|December 12, 2018
A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancerVera Gorbunova, J Thaddeus Beck, Ralf-Dieter Hofheinz, et al.
British Journal of Cancer|July 28, 2019
Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancerVera Gorbunova, J Thaddeus Beck, Ralf-Dieter Hofheinz, et al.
The Lancet. Oncology|March 5, 2018
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trialSibylle Loibl, Joyce O'Shaughnessy, Michael Untch, et al.
Journal of Hepatology|September 1, 2015
Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trialsGregory J Dore, Brian Conway, Yan Luo, et al.
Translational Psychiatry|December 17, 2021
Trauma and posttraumatic stress disorder modulate polygenic predictors of hippocampal and amygdala volumeYuanchao Zheng, Melanie E Garrett, Delin Sun, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
British Journal of Cancer|December 12, 2018
A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancerVera Gorbunova, J Thaddeus Beck, Ralf-Dieter Hofheinz, et al.
British Journal of Cancer|July 28, 2019
Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancerVera Gorbunova, J Thaddeus Beck, Ralf-Dieter Hofheinz, et al.
The Lancet. Oncology|March 5, 2018
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trialSibylle Loibl, Joyce O'Shaughnessy, Michael Untch, et al.
Journal of Hepatology|September 1, 2015
Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trialsGregory J Dore, Brian Conway, Yan Luo, et al.
Translational Psychiatry|December 17, 2021
Trauma and posttraumatic stress disorder modulate polygenic predictors of hippocampal and amygdala volumeYuanchao Zheng, Melanie E Garrett, Delin Sun, et al.
Pageof 2